BioWorld

Feb. 16, 2005

View Archived Issues

Aphton's Insegia Misses In Pancreatic Cancer Phase III

Aphton Corp.'s stock fell more than 45 percent Tuesday following news that its lead pancreatic cancer drug, Insegia, failed to meet the primary endpoint in a Phase III trial. (BioWorld Today) Read More

Vertex, Avalon Sign $73M Cancer Drug Agreement

Read More

Kinase Inhibitor Profiling Method Gives New Therapeutic Insights

Read More

Crawford Receives Bush's Nomination As FDA Head

Read More

Other News To Note

Read More